Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06230770 · ClinicalTrials.gov registry record
Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT
A clinical trial of Contraception and Gender, sponsored by University of California, San Diego.
- Active
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT06230770 is a study of Contraception and Gender that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 160 participants, below the 452-participant average among 72 other Contraception trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06230770, a study of Contraception and Gender, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.
Conditions Studied
Interventions
- BEHAVIORAL Bleeding data
Study Locations (1)
California
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06230770
The ClinicalTrials.gov registry entry for NCT06230770 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 452-participant average among 72 other Contraception trials with a reported enrollment target (65% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Bleeding data is the first listed.
NCT06230770 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06230770 about?
NCT06230770 is a clinical study titled "Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT". Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate G...
What is the current status of trial NCT06230770?
This trial is currently active not recruiting. The enrollment target is 160 participants. The study started on 2024-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06230770 study?
This clinical trial studies the following conditions: Contraception, Gender.
What interventions are being tested in trial NCT06230770?
The interventions under investigation include: Bleeding data (BEHAVIORAL).
Who is sponsoring clinical trial NCT06230770?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06230770 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.